Inovio Pharmaceuticals (NYSE:INO) Loss Widens in Fiscal First Quarter – INO, MRK, PPHM, PFE

Inovio Pharmaceuticals Inc (NYSE:INO) on Friday announced fiscal Q1 net loss was $8.86 million or $0.06 per share, evaluated against $8.3 million or $.06 per share in previous year.

Revenue for three months period plunged to $1.5 million from $1.7 million in same period a year earlier, mainly hurt by the timing of work performed under a deal with the National Institute of Allergy and Infectious Diseases.

Thomson Reuters analysts survey on average forecasted a loss of $0.04 per share on $1.01 million of revenues.

Total quarterly costs for three months period hiked to $8.9 million from $5.9 million in similar period a year ago, and comprised $5 million of research costs.

Shares of the company plunged 2.76% to settle at $0.60 in extended trading session on the NYSE.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Merck & Co., Inc. (NYSE:MRK) rose +1.01% to settle at $45.95, Peregrine Pharmaceuticals (NASDAQ:PPHM) moved up +2.17% to end at $1.41 while Pfizer Inc. (NYSE:PFE) jumped +0.42% to finish at $28.72 on Tuesday.

Inovio Pharmaceuticals Inc (NYSE:INO) last session’s volume of 836,283 shares was lower than its average volume of 1.49 million shares. The stock after opening at $0.61 hit high price of $0.62 and then closed at $0.617 by scoring +0.97%.

INO generated revenue of $4.12 million in the previous twelve months and earned -$19.67 million. The Company showed a negative -478.63% in the net profit margin as well as in its operating margin which remained at -570.42%. Company’s annual sales growth for the past five years was -3.04%.

The INO’s past twelve months’ price to sales ratio was 27.08 and price to cash ratio remained 8.16. As far as the returns are concerned, INO’s return on equity was recorded as -48.17% and return on investment decreased F% while its return on asset stayed at -37.11%.

The stock showed weekly upbeat performance of 3.33% which was maintained for the month at 5.08%. Likewise the negative performance for the quarter was recorded as -20.51% and for the year was 24.00% while the YTD performance remained at 24.00%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines, Latest Picks and tagged , , , , , , , , , , , . Bookmark the permalink.